Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from the panel’s planned meeting next week are confirming many industry ...

In adults 60 and over, vaccine effectiveness from October 2023 to March 2024 against RSV-associated hospitalization reached 75% (95% CI 50-87), according to researchers led by Diya Surie ...

A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

Published in the Journal of the American Medical Association (JAMA), the letter says that the dismissal of the advisors and ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Robert F. Kennedy Jr. dismissed all members of the CDC’s Advisory Committee on Immunization Practices, which recommends which ...

Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ETCompany ParticipantsLavina Talukdar - Senior VP ...

F or the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...